Effective partnering and China market assessment platform – ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations.
Who should present?
Global pharma/biotech companies:
- Looking for out-licensing opportunities in China
- With clinical-stage assets
- Focusing on Oncology, CNS, Cardiovascular, Ophthalmology, Orthopedics, Pediatrics, and GI areas
- Looking for equity investment opportunities in China (Chinese companies only)
Who are the attendees?
- 50% are Chinese pharma/biotechs looking for in-licensing opportunities to enrich pipeline
- 25% are Pharma/biotechs outside China looking for in-licensing opportunities to enrich pipeline in China and other regions
- 15% are VCs and PEs looking for pharma/biotech investment opportunities in China
Why China ?
In/out-licensing is becoming the major business strategy among Chinese pharma.
China related licensing transactions greatly increased despite of COVID-19 in 2020. There were total 129 China related cross border licensing deals including 36 out-licensing deals and 93 in-licensing deals, representing an increase of 59% y/y. Most notably, out-licensing deals reached 36 in 2020, versus 6 in 2019.
Why ACCESS CHINA ?
Broad Chinese Strategic Partners Coverage
Compared to other conferences such as Bio Convention or Bio Showcase, ACCESS CHINA has the broadest coverage of Chinese strategic partners and investors who are looking for in/out licensing opportunities.
Easy China Market Assessment
We gather interests for presenting companies within two weeks after the presentations, an easy and effective way to assess the level of interest in the Chinese market.
More Exposure via Different Channels
ACCESS CHINA promotes presenting companies through various channels in deluding asset listing on platform, video roadshow on live day and on demand, asset report distribution to our members, and promoting to targeted investors through email and social media.
ACCESS CHINA Biotech Forum is a quarterly corporate access event series between China and Western biopharma. It is a leading deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market, and for Chinese companies to enter the global market.
We cordially invite you to join our “ACCESS CHINA Biotech Forum @JPM Week 2022” to be held online from January 4thto 13th, 2022. As the largest CHINA corporate access event during the JPM WEEK in 2022, the forum expects to have over 1000 participants from China pharma and Biotech companies. The two-week event is divided…Keep reading
ACCESS CHINA is a series of events that YAFO organizes each year, including ACCESS CHINA Biotech Forum Summer showcase, East Meets West Mixing Dinner @ JPM, ACCESS CHINA BD Forum @ BIO International Convention, CHINA BD Forum (September each year), and ACCESS CHINA Online Partnering. During 2020 we have helped 333 companies to present their products in front of global pharma and VC/PEs. 5 of them have closed deals after presenting.